No definition available.
Malignant neoplasm of adrenal gland, excluding all cancers (controls excluding all cancers)
C3_ADRENAL_GLAND_EXALLC
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
3 out of 7 registries used, show all original rules. |
255 |
4. Check minimum number of eventsNone |
255 |
5. Include endpointsNone |
255 |
6. Filter based on genotype QC (FinnGen only) |
255 |
Control definitions (FinnGen only)
- Control exclude
- C3_CANCER, C3_CANCER_WIDE_EXALLC
Extra metadata
- First used in FinnGen datafreeze
- DF12
Similar endpoints
↥List of similar endpoints to
Malignant neoplasm of adrenal gland, excluding all cancers (controls excluding all cancers)
based on the number of shared cases.
Similar with more cases:
- Malignant neoplasm of endocrine gland, excluding all cancers (controls excluding all cancers)
- Malignant neoplasm, excluding all cancers (controls excluding all cancers)
- Malignant neoplasm, wide definition for exclusion
- Malignant neoplasm, wide definition for exclusion, excluding all cancers (controls excluding all cancers)
- Any event in hilmo or specialist outpatient
Similar with less cases:
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
This endpoint is excluded (different definition than used in FinnGen).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 255 | 134 | 121 |
| Unadjusted period prevalence (%) | 0.05 | 0.05 | 0.05 |
| Median age at first event (years) | 57.38 | 53.02 | 62.22 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 126
- Matched controls
- 1260
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
D44.1
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Adrenal gland
638.9
87.5
77
*
130
Kela drug reimbursment
Malignant tumour
+∞
59.1
52
*
C74.0
ICD-10 Finland
Malignant neoplasm: Cortex of adrenal gland
+∞
54.1
48
*
BCA31
NOMESCO Finland
Endoscopic unilateral adrenalectomy
+∞
54.1
48
*
C74.1
ICD-10 Finland
Malignant neoplasm: Medulla of adrenal gland
+∞
39.7
36
*
8700/3-C74.9
ICD-O-3
Pheochromocytoma, NOS, of adrenal gland, NOS
+∞
39.7
36
*
BCA30
NOMESCO Finland
Unilateral adrenalectomy
+∞
38.5
35
*
E27.5
ICD-10 Finland
Adrenomedullary hyperfunction
+∞
38.5
35
*
C74.9
ICD-10 Finland
Malignant neoplasm: Adrenal gland, unspecified
+∞
37.4
34
*
H02AB09
ATC
hydrocortisone; systemic
35.6
29.7
38
15
D35.0
ICD-10 Finland
Benign neoplasm: Adrenal gland
324.3
26.8
26
*
TPH07
NOMESCO Finland
Cathetrisation of artery
13.1
25.9
49
58
8370/3-C74.0
ICD-O-3
Adrenal cortical carcinoma of cortex of adrenal gland
+∞
24.8
23
*
8700/3-C74.1
ICD-O-3
Pheochromocytoma, NOS, of medulla of adrenal gland
+∞
23.7
22
*
L01XX23
ATC
mitotane; oral
+∞
22.6
21
*
A03FA01
ATC
metoclopramide; systemic, rectal
9.7
20.0
44
66
WX302
NOMESCO Finland
Thoracal epidural anesthesy
34.2
19.6
25
9
A04AA02
ATC
granisetron; systemic, transdermal
+∞
19.3
18
*
JN4BD
NOMESCO Finland
Extensive body CT
15.4
18.6
31
26
H02AB02
ATC
dexamethasone; systemic
47.0
16.9
20
5
XW000
NOMESCO Finland
Bone marrow biopsy
26.3
16.2
22
10
H02AA02
ATC
fludrocortisone; oral
+∞
16.0
15
*
BC1CD
NOMESCO Finland
Very extensive CT of adrenal glands
+∞
16.0
15
*
9500/3-C74.1
ICD-O-3
Neuroblastoma, NOS, of medulla of adrenal gland
+∞
14.9
14
*
A04AA01
ATC
ondansetron; systemic, rectal
13.0
12.1
21
19
JN3AD
NOMESCO Finland
Abdominal CT examination
11.3
11.8
22
23
WF003
NOMESCO Finland
Adjuvant radiotherapy
+∞
11.6
11
*
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
+∞
11.6
11
*
BC1AD
NOMESCO Finland
CT of adrenal glands
131.5
11.6
12
*
JN3CG
NOMESCO Finland
Extensive MRI examination of abdomen with high intensity magnet
131.5
11.6
12
*
WX402
NOMESCO Finland
General anaesthesia
5.0
11.2
40
108
WX408
NOMESCO Finland
General anesthesy, balanced
4.1
11.0
54
196
BC5AQ
NOMESCO Finland
Chromaffine tissue SPECT with low dose CT
+∞
10.6
10
*
L03AA02
ATC
filgrastim; parenteral
+∞
10.6
10
*
C79.8
ICD-10 Finland
Secondary malignant neoplasm of other specified sites
+∞
10.6
10
*
B01AB05
ATC
enoxaparin; parenteral
4.0
10.5
50
177
B01AB10
ATC
tinzaparin; parenteral
12.9
10.4
18
16
JN4AD
NOMESCO Finland
Body CT examination
16.4
10.3
16
11
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
11.0
10.2
19
20
WX404
NOMESCO Finland
Intravenous generell anesthesy
4.5
10.0
39
114
ZX012
NOMESCO Finland
Radiotherapy with large shaped fields - isocentric therapy
+∞
9.5
9
*
WZC20
NOMESCO Finland
Multidisciplinary treatment meeting
12.9
9.4
16
14
Z31.5
ICD-10 Finland
Genetic counselling
12.0
9.1
16
15
WW500
NOMESCO Finland
Blood transfusion
15.6
8.9
14
10
GD1AA
NOMESCO Finland
Thorax X-ray examination
3.2
8.6
64
310
WZC30
NOMESCO Finland
Teaching
5.0
8.3
27
65
JN4CD
NOMESCO Finland
Very extensive body CT
35.9
8.2
10
*
A49.9
ICD-10 Finland
Bacterial infection, unspecified
6.4
8.1
21
38
JN3BD
NOMESCO Finland
Extensive abdominal CT
6.4
8.1
21
38
N02AB03
ATC
fentanyl; nasal, sublingual, transdermal
17.0
7.4
11
7
WB123
NOMESCO Finland
Demanding adjuvant cytostatic therapy
+∞
7.4
7
*
105
Kela drug reimbursment
Adrenal cortical hypofunction
+∞
7.4
7
*
WD115
NOMESCO Finland
Multiple cystostatic therapy of methastized malignancy
+∞
7.4
7
*
8010/3-C74.9
ICD-O-3
Carcinoma, NOS, of adrenal gland, NOS
+∞
7.4
7
*
C61
ICD-10 Finland
Malignant neoplasm of prostate
+∞
7.4
7
*
WD225
NOMESCO Finland
Demanding therapy of methastized malignancy with hormones
+∞
7.4
7
*
8370/3-C74.9
ICD-O-3
Adrenal cortical carcinoma of adrenal gland, NOS
+∞
7.4
7
*
C78.7
ICD-10 Finland
Secondary malignant neoplasm of liver and intrahepatic bile duct
+∞
7.4
7
*
2533
FHL
Unilateral removal of additional egg
+∞
7.4
7
*
8140/3-C61.9
ICD-O-3
Adenocarcinoma, NOS, of prostate gland
+∞
7.4
7
*
ZX070
NOMESCO Finland
Intensity modified radiotherapy
+∞
7.4
7
*
E24.9
ICD-10 Finland
Cushing syndrome, unspecified
+∞
7.4
7
*
D41.0
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Kidney
17.9
6.9
10
6
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
3.9
6.8
29
90
E27.3
ICD-10 Finland
Drug-induced adrenocortical insufficiency
42.4
6.8
8
*
XX1XW
NOMESCO Finland
Extensive written report from radiologist
42.4
6.8
8
*
WZC00
NOMESCO Finland
Planning of intervention or health care consultation
2.9
6.7
50
234
WX602
NOMESCO Finland
Repeated or continuing anesthesia shots throug a catheter
5.4
6.6
19
40
TPH90
NOMESCO Finland
Removal of fixed intravenous catheter
15.4
6.5
10
7
JN3DG
NOMESCO Finland
Very extensive MRI examination with high intensity magnet
73.4
6.5
7
*
WD105
NOMESCO Finland
Cystostatic therapy of methastized malignancy
73.4
6.5
7
*
XX3DW
NOMESCO Finland
Time consuming IT work
6.0
6.4
17
32
ZX120
NOMESCO Finland
Intravenous
5.0
6.4
20
46
R50.9
ICD-10 Finland
Fever, unspecified
3.9
6.4
26
78
JN3CD
NOMESCO Finland
Abdominal CT examination both without and with contrast
19.2
6.4
9
5
116
Kela drug reimbursment
Prostate cancer
+∞
6.3
6
*
XX9AN
NOMESCO Finland
Complementary isotope examination or additional picture
+∞
6.3
6
*
WD135
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
+∞
6.3
6
*
E27.1
ICD-10 Finland
Primary adrenocortical insufficiency
+∞
6.3
6
*
WF049
NOMESCO Finland
Radiotherapy of metastasis
+∞
6.3
6
*
C78.0
ICD-10 Finland
Secondary malignant neoplasm of lung
+∞
6.3
6
*
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
96
34
44.68
149.93
4.3
1.2
—
—
nmol/l
—
0
0
57
27
26.90
78.36
1.4
1.2
229.3
486.6
pmol/l
1.51
46
21
47
18
31.79
69.53
1.2
1.6
—
—
—
0
0
37
10
43.11
60.37
7.4
1.3
24.3
19.1
ug/l
—
37
10
166
904
3.40
19.55
12.2
4.0
14.1
14.1
umol/l
0.01
160
840
74
248
3.79
19.09
7.8
7.8
1.1
1.1
mmol/l
0.08
69
230
40
86
5.33
18.23
3.4
1.5
4.2
5.8
ug/l
0.17
33
66
163
903
3.23
18.16
14.5
7.1
1.2
1.2
mmol/l
0.40
130
781
48
130
4.32
16.49
6.3
3.3
1.2
1.2
mmol/l
0.14
48
113
146
791
2.98
16.35
5.7
3.7
—
—
—
0
0
17
19
9.52
13.93
1.8
1.4
—
—
—
0
0
49
153
3.73
13.72
2.4
2.4
0.2
0.2
g/l
0.49
44
140
177
1125
2.87
13.72
10.3
4.8
6.5
6.7
mmol/l
0.73
170
1032
53
179
3.48
13.16
6.2
8.3
13.9
11.9
kpa
1.33
48
172
53
179
3.48
13.16
6.2
8.3
5.2
5.2
kpa
0.07
48
171
51
177
3.35
12.08
6.4
8.4
0.7
1.5
mmol/l
0.71
42
140
21
36
6.27
12.00
2.6
2.0
28.1
17.7
u/ml
0.34
16
30
16
21
8.06
11.55
2.6
4.1
17.2
54.9
mu/l
0.53
16
21
37
107
3.88
11.49
1.5
1.4
—
—
—
0
0
66
276
2.88
11.31
2.9
2.2
29.9
29.6
s
0.21
66
267
83
392
2.66
11.24
3.9
2.0
—
—
—
0
0
103
540
2.52
11.23
4.7
3.3
0.3
0.4
e6/l
0.16
86
390
47
164
3.29
10.99
4.8
3.0
—
—
—
0
0
103
554
2.44
10.48
7.1
2.0
2.3
2.4
mmol/l
0.20
97
460
116
659
2.39
10.43
4.6
3.3
—
—
—
0
0
16
24
7.05
10.30
1.8
1.2
—
—
—
0
0
53
206
2.99
10.30
7.4
3.7
11.9
7.4
umol/l
0.27
47
175
50
188
3.06
10.29
1.8
1.7
—
—
—
0
0
20
39
5.48
10.01
1.8
1.5
—
—
—
0
0
62
267
2.75
9.95
2.1
1.7
—
—
—
0
0
20
41
5.21
9.48
1.8
1.5
—
—
—
0
0
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
20
41
5.21
9.48
2.1
4.6
0.4
0.4
u/ml
0.01
15
25
48
191
2.86
8.87
2.0
1.8
—
—
—
0
0
159
1091
2.21
8.51
23.6
6.6
4.0
4.2
e9/l
0.49
148
939
56
249
2.60
8.33
2.1
2.6
25.2
22.6
%
0.36
49
223
16
30
5.62
8.32
1.8
1.3
—
—
—
0
0
23
61
4.05
7.99
3.5
2.3
14.0
9.2
u/l
0.56
17
47
15
28
5.63
7.82
1.5
1.2
—
—
—
0
0
19
44
4.59
7.82
1.4
1.4
—
—
—
0
0
13
21
6.47
7.79
1.4
1.3
—
—
—
0
0
12
9
13.91
7.46
5.2
4.4
—
—
—
0
0
10
5
20.72
7.19
1.9
1.2
40.2
1.8
umol/24h
—
10
5
101
611
2.08
7.17
4.9
3.0
31.4
31.2
u/l
0.02
95
576
10
13
7.97
7.17
1.7
1.3
—
—
—
0
0
14
27
5.43
7.05
2.9
3.3
15.1
17.1
%
—
8
13
40
166
2.67
6.77
21.1
12.4
24.7
24.9
mmol/l
0.10
40
166
24
75
3.43
6.61
2.9
2.1
21.2
16.6
iu/l
0.28
19
61
59
298
2.27
6.54
2.2
2.5
11.7
13.8
umol/l
1.27
59
274
17
43
4.16
6.27
1.1
1.3
—
—
—
0
0
15
38
4.13
5.52
3.0
1.4
—
—
—
0
0
16
44
3.81
5.29
1.4
3.3
—
—
—
0
0
25
93
2.87
5.18
1.6
1.6
—
—
—
0
0
79
485
1.91
5.09
2.2
2.2
3.1
2.9
mg/l
0.22
69
417
10
19
5.44
5.08
1.1
1.1
—
—
—
0
0
10
19
5.44
5.08
1.9
1.2
—
—
—
0
0
165
1278
1.82
4.92
4.3
3.1
75.7
44.4
u/l
1.96
155
1188
57
316
2.04
4.91
4.2
3.2
2.7
2.2
e6/l
0.18
32
171
36
166
2.36
4.87
6.6
8.8
1.9
1.5
mmol/l
0.32
31
120
9
10
9.28
4.82
1.8
1.2
—
—
—
0
0
34
160
2.30
4.40
2.4
1.9
25.5
32.0
u/l
1.21
28
131
12
31
4.01
4.31
1.9
7.9
—
267.4
—
0
5
7
6
11.94
4.30
2.0
1.2
—
—
—
0
0
187
1536
1.82
4.25
5.9
3.7
14.7
14.8
pmol/l
0.36
174
1385
25
105
2.53
4.13
6.5
10.6
9.3
9.4
kpa
0.18
25
97
11
28
4.06
4.02
1.8
1.4
—
—
—
0
0
58
348
1.86
3.92
4.0
2.8
0.3
0.9
e6/l
3.65
32
202
6
5
12.24
3.78
1.3
3.6
—
—
—
0
0
7
9
7.96
3.58
2.6
1.3
5.4
4.0
nmol/l
—
7
9
156
1251
1.64
3.54
5.4
4.1
7.8
31.1
e6/l
—
5
15
6
6
10.20
3.51
2.2
1.2
—
—
—
0
0
177
1468
1.67
3.49
4.7
4.1
15.7
11.3
mm/h
2.65
167
1331
58
361
1.79
3.46
4.2
3.6
731.0
219.1
ng/l
0.47
45
268
6
7
8.74
3.28
2.3
1.9
—
—
—
0
0
12
38
3.26
3.25
2.1
1.7
—
—
—
0
0
11
33
3.44
3.23
2.7
3.5
53.9
55.1
%
0.08
11
33
113
856
1.57
3.13
3.3
2.8
203.2
97.3
ug/l
2.49
108
794
6
8
7.65
3.07
2.2
1.1
—
—
—
0
0
65
433
1.67
3.02
1.6
1.5
18.7
21.5
nmol/l
0.82
60
365
102
760
1.57
3.00
3.2
2.5
76.2
75.9
nmol/l
0.03
97
670
8
17
4.82
2.94
2.0
1.1
—
—
—
0
0
6
9
6.79
2.88
2.0
1.6
—
—
—
0
0
10
31
3.32
2.80
1.2
1.2
—
—
—
0
0
10
31
3.32
2.80
1.2
1.2
—
—
—
0
0
8
20
4.09
2.59
1.9
1.3
—
—
—
0
0
7
16
4.47
2.49
1.6
1.0
—
—
—
0
0
8
22
3.72
2.38
1.9
1.3
—
—
—
0
0
8
23
3.56
2.29
1.1
1.3
—
—
—
0
0
37
228
1.73
2.27
21.4
5.6
2.2
1.9
mmol/l
0.30
31
179
6
14
4.36
2.16
1.0
1.0
—
—
—
0
0
11
44
2.57
2.04
1.3
2.1
—
—
—
0
0
73
547
1.47
1.97
3.1
3.3
3115.8
1313.2
ng/l
0.80
58
455
54
385
1.51
1.85
1.9
1.7
448.8
448.5
pmol/l
0.00
44
307
205
1865
1.51
1.83
6.0
4.5
1.8
2.0
mu/l
0.60
189
1686
5
12
4.23
1.83
1.6
1.3
—
—
—
0
0
7
23
3.10
1.81
1.0
1.6
—
—
—
0
0
11
47
2.40
1.80
1.6
1.9
—
—
—
0
0
10
41
2.50
1.77
2.3
1.2
—
1.1
—
0
5
5
13
3.90
1.72
1.4
1.8
—
—
—
0
0
0
48
0.00
1.71
0.0
1.6
—
—
—
0
0
13
249
0.50
1.70
11.3
6.9
—
—
—
0
0
8
32
2.55
1.61
1.1
1.3
—
—
—
0
0
6
141
0.41
1.58
1.0
1.1
—
—
—
0
0
0
42
0.00
1.54
0.0
1.8
—
—
—
0
0
63
483
1.40
1.48
3.4
2.5
333.5
8816.8
umol/l
2.49
55
417
190
1730
1.39
1.46
39.7
13.4
14.0
13.5
%
4.35
185
1697
193
1765
1.38
1.42
27.3
9.8
81.9
81.5
ml/min/173m2
0.10
171
1388
5
17
2.98
1.36
1.0
1.0
—
—
—
0
0
63
490
1.38
1.36
3.6
3.8
0.0
0.0
estimate
0.00
31
166
0
39
0.00
1.35
0.0
1.4
—
—
—
0
0
112
954
1.31
1.32
3.9
3.7
0.0
0.0
estimate
0.50
35
165
9
44
2.08
1.28
1.3
1.8
—
—
—
0
0
110
938
1.30
1.27
5.8
5.1
0.0
0.0
estimate
0.00
36
166
110
943
1.29
1.21
3.9
3.6
0.0
0.0
estimate
0.00
35
169
203
1892
1.36
1.16
4.4
4.3
5.9
5.9
mmol/l
0.13
194
1711
85
709
1.30
1.14
4.6
3.5
30.0
41.3
ng/l
0.79
62
484
22
147
1.54
1.04
3.5
2.3
59.9
65.6
ml/min/173m2
—
10
53
52
410
1.34
1.03
2.6
1.8
1.4
0.9
mg/l
0.93
37
309
9
51
1.79
0.95
1.2
1.6
1.1
0.7
nmol/l
—
9
42
16
103
1.59
0.90
1.6
1.5
—
—
—
0
0
10
166
0.59
0.87
1.6
1.7
—
—
—
0
0
10
57
1.79
0.85
2.1
1.6
—
—
—
0
0
122
1346
0.82
0.82
3.0
3.1
—
—
—
0
0
87
756
1.23
0.80
1.9
1.8
82.2
95.6
pmol/l
1.88
41
367
0
24
0.00
0.79
0.0
1.1
—
—
—
0
0
32
409
0.75
0.77
1.5
1.8
—
—
—
0
0
192
1813
1.24
0.75
6.1
5.7
40.0
39.9
mmol/mol
0.02
185
1677
20
144
1.42
0.70
1.3
1.2
62.9
87.2
iu/ml
—
10
58
10
61
1.67
0.69
2.0
1.6
—
—
—
0
0
41
499
0.79
0.69
1.3
1.5
0.8
2.3
u/ml
1.54
11
125
5
27
1.87
0.69
1.2
1.6
—
—
—
0
0
60
515
1.22
0.62
2.5
1.6
2.0
1.4
mmol/l
0.95
54
441
0
20
0.00
0.60
0.0
1.0
—
18.9
—
0
20
6
36
1.68
0.57
1.2
1.2
—
—
—
0
0
18
238
0.74
0.56
3.6
4.9
32.7
31.1
%
0.22
13
148
6
98
0.60
0.53
2.0
1.5
—
—
—
0
0
80
716
1.17
0.53
4.0
3.7
—
—
—
0
0
9
64
1.42
0.52
2.2
1.1
9.4
11.3
g/l
—
9
57
6
40
1.51
0.52
1.3
1.4
—
—
—
0
0
69
612
1.17
0.50
4.2
3.9
24.6
39.3
mg/mmol
0.20
43
380
209
2017
1.20
0.50
27.6
11.1
30.6
21.8
mg/l
2.92
190
1513
199
1919
1.17
0.44
4.6
4.4
4.8
4.6
mmol/l
1.09
184
1775
28
231
1.24
0.43
35.5
23.3
1.7
1.3
inr
—
5
34
5
33
1.53
0.41
1.2
1.2
—
—
—
0
0
0
16
0.00
0.41
0.0
1.0
—
—
—
0
0
0
17
0.00
0.41
0.0
1.1
—
—
—
0
0
36
418
0.84
0.40
4.2
3.8
1.0
1.0
kg/l
0.04
11
63
5
34
1.48
0.40
1.0
1.2
—
—
—
0
0
10
137
0.72
0.40
1.5
1.4
—
51.2
—
0
12
8
115
0.69
0.38
1.0
1.3
—
—
—
0
0
5
37
1.36
0.37
1.0
1.3
60.6
52.4
pmol/l
—
5
37
9
71
1.28
0.36
2.2
1.2
—
—
—
0
0
15
118
1.29
0.34
2.2
1.8
—
—
—
0
0
201
1952
1.14
0.34
5.0
4.9
2.8
2.7
mmol/l
0.38
184
1798
218
2132
1.16
0.31
19.8
8.4
27.0
26.1
u/l
0.25
211
2029
7
54
1.30
0.30
1.0
1.2
—
—
—
0
0
7
57
1.23
0.29
1.7
1.3
—
—
—
0
0
195
1897
1.12
0.29
32.4
12.4
38.1
40.1
%
3.17
142
1378
189
1842
1.10
0.24
4.5
3.9
1.5
1.3
mmol/l
3.49
174
1683
195
1905
1.10
0.23
4.6
4.4
1.4
1.5
mmol/l
0.64
179
1751
38
345
1.12
0.22
2.1
1.7
1296.9
1214.6
nmol/l
0.18
27
264
0
11
0.00
0.21
0.0
1.1
—
—
—
0
0
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
0
12
0.00
0.21
0.0
1.5
—
—
—
0
0
24
213
1.14
0.19
1.9
2.0
—
—
—
0
0
7
58
1.21
0.18
1.3
1.5
—
0.2
—
0
13
5
68
0.73
0.17
1.0
1.2
—
—
—
0
0
5
69
0.72
0.17
1.0
1.2
—
—
—
0
0
37
341
1.10
0.17
2.9
2.5
0.9
0.8
ug/l
0.31
24
216
30
328
0.90
0.16
1.2
1.3
5.2
12.6
u/ml
—
7
128
46
491
0.92
0.16
3.7
3.5
20.3
24.6
%
0.52
24
225
9
78
1.16
0.15
1.8
1.5
—
—
—
0
0
11
93
1.19
0.14
2.0
1.7
—
—
—
0
0
33
356
0.92
0.14
1.3
1.3
49.4
40.0
iu/ml
0.13
14
118
5
47
1.07
0.09
1.0
1.3
—
47.5
—
0
6
6
58
1.04
0.08
1.2
1.1
32.2
39.0
g/l
—
6
50
7
67
1.05
0.08
1.7
1.1
—
—
—
0
0
6
75
0.80
0.07
1.0
1.7
2.3
2.3
mg/l
—
6
49
25
237
1.06
0.06
2.0
2.1
—
—
—
0
0
29
283
1.03
0.01
1.4
1.3
—
—
—
0
0
62
613
1.02
0.01
4.5
3.7
3.1
2.0
ug/l
0.56
51
546
7
69
1.01
0.00
1.4
2.3
—
—
—
0
0
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
7
78
0.89
0.00
1.7
1.7
—
123.3
—
0
6
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
6.2
—
—
—
0
0
0
5
0.00
0.00
0.0
8.6
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.5
—
—
—
0
0
(3011547) Coagulation factor VII activity actual/normal in Platelet poor plasma by Coagulation assay
0
5
0.00
0.00
0.0
1.0
—
131.6
—
0
5
0
5
0.00
0.00
0.0
1.6
—
—
—
0
0
(40770918) von Willebrand factor (vWf).activity actual/normal in Platelet poor plasma by Immunoassay
0
6
0.00
0.00
0.0
2.8
—
115.3
—
0
6
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
5
50
1.00
0.00
1.8
1.5
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
0.00
0.0
6.2
—
—
—
0
0
6
67
0.89
0.00
1.2
1.2
3.3
3.0
g/l
—
6
54
7
71
0.99
0.00
1.1
1.4
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded (different definition than used in FinnGen).
Relationships between endpoints
↥Index endpoint: C3_ADRENAL_GLAND_EXALLC – Malignant neoplasm of adrenal gland, excluding all cancers (controls excluding all cancers)
GWS hits: -
This endpoint is excluded (different definition than used in FinnGen).